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Background: The long-chain n-3 fatty acids eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) have
human health benefits. Alternatives to fish as sources of EPA and DHA are needed. Oil from the micro-algae
Nannochloropsis oculata contains a significant amount of EPA conjugated to phospholipids and glycolipids and no
DHA. Krill oil contains EPA and DHA conjugated to phospholipids. We compare the appearance of fatty acids in
blood plasma of healthy humans after consuming a high fat meal followed by either algal oil or krill oil.
Methods: Ten healthy males aged 18-45 years consumed a standard high fat (55 g) breakfast followed by either
algal oil (providing 1.5 g EPA and no DHA) or krill oil (providing 1.02 g EPA and 0.54 g DHA). All participants
consumed both oils in random order and separated by 7 days. Blood samples were collected before the breakfast
and at several time points up to 10 hours after taking the oils. Fatty acid concentrations (μg/ml) in plasma were
determined by gas chromatography.
Results: Fatty acids derived mainly from the breakfast appeared rapidly in plasma, peaking about 3 hours after
consuming the breakfast, and in a pattern that reflected their content in the breakfast. There were time-dependent
increases in the concentrations of both EPA and DHA with both algal oil (P < 0.001 for EPA; P = 0.027 for DHA) and
krill oil (P < 0.001 for both EPA and DHA). The concentration of EPA was higher with algal oil than with krill oil at
several time points. DHA concentration did not differ between oils at any time point. The maximum concentration
of EPA was higher with algal oil (P = 0.010) and both the area under the concentration curve (AUC) and the
incremental AUC for EPA were greater with algal oil (P = 0.020 and 0.006). There was no difference between oils in
the AUC or the incremental AUC for DHA.
Conclusion: This study in healthy young men given a single dose of oil indicates that the polar-lipid rich oil from
the algae Nannochloropis oculata is a good source of EPA in humans.
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Omega-3 (n-3) fatty acids are a family of polyunsaturated
fatty acids (PUFAs) that have a carbon-carbon double
bond on the third carbon from the methyl end of the
hydrocarbon chain [1]. The two long-chain (LC) n-3 fatty
acids of most importance to human health are eicosa-
pentaenoic acid (EPA; 20:5n-3) and docosahexaenoic
acid (DHA; 22:6n-3) [1]. Since EPA and DHA are poorly
synthesized endogenously in humans [2], they may be
essential and hence, must come from external sources.
Seafood is a good source of EPA and DHA, and also
provides the metabolic intermediate docosapentaenoic
acid (DPA; 22:5n-3). Since the original observations in
Greenland Inuit of an association between high dietary
intake of these marine LC n-3 PUFAs and lowered risk
of cardiovascular disease [3,4], effects clearly linked to
biological functions of the fatty acids, much interest
has been focused on the health benefits of seafood in
general and of marine LC n-3 PUFAs in particular
[5-10].
EPA and DHA have been shown to lower blood triglyc-
erides [11] and the US Food and Drug Administration has
approved two LC n-3 PUFA based prescription drugs for
treating hypertriglyceridemia: Lovaza® (GSK), consisting of
EPA plus DHA, and Vascepa® (Amarin), consisting of EPA
only. Besides lowering blood triglycerides, EPA and DHA
also exert beneficial effects in inflammatory conditions
[12,13]. Furthermore, there is accumulating evidence that
EPA and DHA play an important role in ameliorating
psychiatric and psychological disorders in adults [14,15]
and in slowing cognitive decline in the elderly [16,17].
As a result of these beneficial effects on human health,
particularly the cardio-protective effects, there have been
recommendations that individuals should increase their
daily intake of LC n-3 fatty acids [18,19]. Consequently,
the use of food supplements in the form of oil capsules
containing purified or processed fish oil has become
popular.
Because of sustainability issues, sources of LC n-3
PUFAs other than fish are likely to be increasingly
important. In the last few years, krill oil from Euphausia
superba has become a recognized commercial source of
the LC n-3 fatty acids EPA and DHA [20]. In addition,
EPA and DHA have been found to be produced by other
organisms including micro-algae [21]. Crypthecodinium
cohnii dinoflagellate produces DHA only [22], Schizo-
chytrium unicellular protists produce both EPA and
DHA [23] and the genetically modified Yarrowia
lipolytica yeast produces EPA only [24]. In fish oil the
LC n-3 fatty acids are primarily conjugated to a trigly-
ceride (TAG) backbone, whereas in krill oil the fatty
acids are largely conjugated to phospholipids (PhLs)
[25]. PhLs not only play a role in health [26] but there
is evidence that LC n-3 PUFAs in PhLs have a higherbioavailability than those in TAGs [27]. These properties
suggest that krill oil may have superiority over some other
sources of LC n-3 PUFAs [28]. Recently, various species of
the genus Nannochloropsis have been found to contain
high concentrations of EPA with no DHA [29]. The oil
extracted from the micro-algae Nannochloropsis oculata
comprises up to 8-10% PhLs and 30-40% glycoplipids
[30] as polar-lipids with 30-40% EPA as the major fatty
acid.
There are a growing number of studies that have
shown that EPA and DHA have different biological
effects and potencies. Some studies suggest that of these
two LC n-3 fatty acids, EPA rather than DHA is primarily
responsible for reducing inflammation [31] and depression
[32] and that while both EPA and DHA modify blood lipid
profiles, DHA seems to have the strongest effects [33].
In a recent meta-analysis of studies in depression [15]
it has been suggested that, not only is EPA responsible
for therapeutic effects, but that DHA acts to block the
activity of EPA. The oil extracted from the micro-algae
Nannochloropsis is one of the few sources of EPA without
the presence of DHA and thus presents a means of maxi-
mizing the efficacy of EPA. An important question that
is not well resolved is whether LC n-3 fatty acids (EPA
and DHA) are equally available to the human body
when provided from algal oil or krill oil in which the
fatty acids are present in different forms. Thus, the
present study set out to follow the plasma levels of EPA
and DHA, as well as of other fatty acids, in young healthy
subjects in the period immediately following consumption
of algal oil or krill oil with a high fat meal.
Methods
Subjects and study design
The study had a cross-over design in which all partici-
pants consumed both algal oil and krill oil in random
order separated by 7 days. The study was approved by
the Ethics Committee of the Ärztekammer Hamburg
and the participants provided written informed consent.
Inclusion criteria were: male; 18 to 45 years of age, in-
clusive; body mass index (BMI) ≥ 20 and ≤ 32 kg/m2;
non-smoker; in general good health on the basis of med-
ical history, and laboratory values, physical examination,
vital signs and 12-lead electrocardiogram at screening;
willingness to adhere to the study protocol; willingness
to refrain from consumption of oily fish more than once
a week during the study period. Exclusion criteria were:
clinically relevant abnormal laboratory test results at
screening; history or presence of clinically important
metabolic, endocrine (including type 1 or type 2 diabetes),
cardiovascular, hepatic, renal, hematologic, immunologic,
gastrointestinal, neurologic, psychiatric or biliary disor-
ders; recent history of (within 12 months of screening) or
strong potential for alcohol or substance abuse; con-
Table 1 Fatty acid composition of study supplements
Fatty acid Algal oil Krill oil
Lauric (12:0) 0.33 0.14
Myristic (14:0) 2.48 5.02
Myristoleic (14:1n-5) - 0.36
Pentadecanoic (15:0) 0.28 0.19
Palmitic (16:0) 9.63 12.05
Palmitoleic (16:1n-7) 11.68 3.31
Heptadecanoic (17:0) 0.11 0.06
Stearic (18:0) 0.14 0.58
Oleic (18:1n-9) 1.06 5.96
Cis-Vaccenic (18:1n-7) 0.35 3.93
Linoleic (18:2n-6) 1.24 1.05
γ-Linolenic (18:3n-6) 0.16 0.08
Dihomo-γ-linolenic (20:3n-6) 0.42 -
Arachidonic (20:4n-6) 5.3 0.37
Eicosapentaenoic (EPA; 20:5n-3) 25.06 13.63
Docosapentaenoic (DPA; 22:5n-3) - 0.32
Docosahexaenoic (DHA; 22:6n-3) - 7.17
Others 11.14 5.75
Total 69.38 65.04
Data are % of oil.
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prescription drug within 2 weeks before clinic visit 1 and
use of any over-the-counter drug within 1 week before
clinic visit 1; use of any anti-inflammatory medication
within four weeks of clinic visit 1 or during the study
period; use of any lipid-lowering medication within four
weeks of clinic visit 1 or during the study period; con-
sumption of fish oil or other oil supplements within 3
weeks before clinic visit 1 or during the study period;
known allergy or sensitivity to n-3 fatty acids, fish or
seafood; inability to provide written informed consent.
Ten subjects were recruited into the study.
The two different oil supplements used were: QH101
polar-lipid rich algal oil from the micro-algae Nanno-
chloropsis oculata (Qualitas Health Ltd., Jerusalem,
Israel), and a commercially available krill oil supplement
(NKO; Neptune Technologies & Bioresources Inc.,
Quebec, Canada). Both oils were encapsulated in gel-
atin soft capsules manufactured by Catalent, Eberbach,
Germany.
On days 1 and 8 the participants arrived in the morn-
ing after overnight fasting. They were provided a high
fat breakfast, after which the test oil supplements were
immediately administered. The high fat test meal com-
prised toast with jam or marmalade (to provide the
carbohydrate) and a milkshake made from milkshake
powder, double cream, oils (safflower, linseed and olive)
and water. The total energy content of the meal was 4.3
kJ and it provided 55 g fat, 130 g carbohydrate and 12 g
protein. The major fatty acids in the meal were oleic acid
(34% of fatty acids), linoleic acid (22.1%), palmitic acid
(21.5%), stearic acid (8.4%), and α-linolenic acid (3.7%).
The supplement capsules were swallowed with 200 ml
of water to provide ~1.5 g EPA+DHA. For the algal oil
this was purely as EPA with no DHA present while for
krill oil this was as 1.02 g EPA and 0.54 g DHA. In order
to provide this amount of LC n-3 fatty acids 9 capsules
of algal oil or 14 capsules of krill oil were administered.
Participants had nothing further to drink except water
or tea until the last blood sample was collected. A
standardized low-fat snack was provided after 6 hours.
Blood samples for the analysis of plasma fatty acid con-
centrations were collected before the breakfast and 0.5,
1, 1.5, 2, 2.5, 3, 4, 5, 6, 8 and 10 hours after taking the
supplements. Blood samples were centrifuged at 1500 x
g at room temperature for 15 minutes. Plasma was col-
lected and stored at -80°C until shipping to the Univer-
sity of Southampton, Southampton, UK for analysis.
Quantitative analysis of krill oil and algal oil
Analysis of the fatty acid content of the algal and krill
oils was performed by an external laboratory (New Jersey
Feed Labs, NJ, USA) according to the AOAC 963.22
standard using a Shimadzu 17A gas chromatograph. Thefull fatty acid composition of each supplement is pre-
sented in Table 1. The phospholipid content of the two
oils was elucidated by 31P NMR spectroscopy and the
glycolipids and cholesterol content by 1H NMR spectros-
copy. Both methods used a BRUKER Avance III 600 MHz
Nuclear Magnetic Resonance Spectrometer performed
by Spectral Services, Cologne, Germany. The polar lipid
and cholesterol contents of the two supplements are
shown in Table 2. Krill oil was rich in phosphatidylcholine
and other PhLs, but did not contain glycolipids. Algal oil
contained some PhLs and a greater amount of glycolipids.
Fatty acid composition analysis of human plasma
Fatty acids were analyzed in the total lipid fraction of
human plasma, essentially using the procedure described
in Browning et al. for plasma lipid fractions [34]. Prior
to lipid extraction internal standard (di-15:0 phosphat-
idylcholine; 100 μg) was added to plasma to enable
quantification of fatty acids. Thawed plasma (0.6 ml)
was mixed vigorously with 5 ml chloroform:methanol
(2:1 vol/vol); butylated hydroxytoluene (50 mg/l) was
included in the chloroform:methanol as antioxidant.
After centrifugation the organic phase that includes the
extracted plasma lipid was collected. This was dried
down under nitrogen at 40°C and redissolved in 0.5 ml
toluene. Fatty acid methyl esters (FAMEs) were formed
by incubation of the entire lipid extract with 1 ml
methanol containing 2% (vol/vol) H2SO4 at 50°C for 2 hr.
Table 2 Polar lipid and cholesterol contents of the
study supplements
Lipid Algal oil Krill oil
Phosphatidylcholine 2.34 26.77
1-Lysophosphatidylcholine - 0.32






Other phospholipid 0.94 0.37
Digalactosydiacylglycerol 8.8 -
Monogalactosydiacylglycerol 2.5 -
Total polar lipids 17.25 33.39
Cholesterol 0.05 2.1
Data are % of oil. Neither oil contained detectable amounts of
lysophosphatidylinositol, phosphatidylserine, lysophosphatidylserine,
sphingolipids, diphosphatidylglycerol, phosphatidic acid or
lysophosphatidic acid.
Table 3 Characteristics of the participants
Age (years) 35.3 ± 5.8
Systolic blood pressure (mm-Hg) 123 ± 13
Diastolic blood pressure (mm-Hg) 76.0 ± 6.4
Weight (kg) 82.5 ± 5.4
Body mass index (kg/m2) 25.6 ± 1.5
Data are mean ± SD for 10 participants.
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by addition of 1 ml of a solution of 0.25 M KHCO3 and
0.5 M K2CO3. Then FAMEs were extracted into 1 ml hex-
ane, dried down, redissolved in a small volume (150 μl) of
hexane, and separated by gas chromatography. Gas chro-
matography was performed on a Hewlett Packard 6890
gas chromatograph fitted with a BPX-70 column (30 m ×
0.22 mm× 0.25 μm). Inlet temperature was 300°C. Oven
temperature was initially 115°C and this was maintained
for 2 min post-injection. Then the oven temperature was
programmed to increase to 200°C at the rate of 10°C/min,
to hold at 200°C for 16 min, and then to increase to 240°C
at the rate of 60°C/min and then to hold at 240°C for 2
min. Total run time was 37 min. Helium was used as the
carrier gas. FAMEs were detected by a flame ionization
detector held at a temperature of 300°C. The instrument
was controlled by, and data collected using, HPChemStation
(Hewlett Packard). FAMEs were identified by comparison
of retention times with those of authentic standards run
previously. Absolute concentrations of fatty acids were
calculated using the 15:0 internal standard.
Statistical analyses
Data are presented as mean and SD. The area under the
plasma concentration-time curve (both the total area
under the concentration curve (AUC) and the incremental
area under the concentration curve (IAUC)) from baseline
up to the last measurement was calculated by linear up-
logarithmic down trapezodial summation. Two-factor ana-
lysis of variance with repeated measurements (MANOVA)
was applied for analyzing the time x oil effect (the differ-
ences in measurements (μg/ml)) over all time pointsbetween the oil types. One-way analysis of variance with
repeated measurements was applied for analyzing the
trend over time (12 time-points) and for testing the hy-
pothesis that the trend is different from 0 within each
treatment group. The paired t-test was used for testing
the statistical significance of the change from time 0
(baseline) to all other time points within each study group
and for testing the statistical significance of the difference
between krill oil and algal oil. All tests applied were
two-tailed, and a p-value of < 0.05 was considered sta-
tistically significant. Data were analyzed using the SASW




Ten healthy males participated in this study. Their char-
acteristics are shown in Table 3. All participants com-
pleted both arms of the trial and all samples were
collected. There were no indications of intolerance to
either supplement.
Fasting plasma fatty acids
Fasting concentrations of fatty acids averaged over the
two clinic visits are shown in Table 4. The major fatty
acids present in fasting plasma were linoleic (27.7% of
total plasma fatty acids), oleic (23.4%), and palmitic
(23%), followed by stearic (7.1%) and arachidonic (6.6%).
Mean fasting concentrations of EPA and DHA were 25.6
and 55.8 μg/ml, respectively, representing 0.75 and
1.63% of total fatty acids, respectively.
Changes in plasma fatty acids
The changes in concentration of individual fatty acids in
plasma are shown in Figure 1, which shows fatty acids of
14 to 18 carbon chain length, and Figure 2, which shows
PUFAs of 20 and 22 carbon chain length. Increases in
fatty acid concentrations were seen at the first post-meal
blood sampling time point (30 minutes). Oleic, palmitic
and linoleic acids showed the greatest increases in con-
centration (Figure 1), which is consistent with these fatty
acids being the most abundant in the test meal. There
were no differences in the concentration, or in the
change in concentration, of any 14 to 18 carbon chain
Table 4 Fasting concentrations of plasma fatty acids and Tmax, Cmax, and MaxΔC for each fatty acid following
consumption of the test meal with algal oil or krill oil
Algal oil Krill oil
Fatty acid Fasting concentration (μg/ml) Tmax (hr) Cmax (μg/ml) MaxΔC (μg/ml) Tmax (hr) Cmax (μg/ml) MaxΔC (μg/ml)
Myristic 37.8 ± 4.7 3.0 ± 1.6 107.7 ± 62.4 66.0 ± 39.3 3.2 ± 1.5 98.7 ± 46.9 65.8 ± 39.8
Palmitic 783.6 ± 97.9 3.1 ± 1.7 1106 ± 448 320.7 ± 222.1 3.2 ± 1.9 1024 ± 332 263.8 ± 142.8
Palmitoleic 67.4 ± 9.1 3.2 ± 1.9 97.2 ± 71.5 27.6 ± 18.8 3.0 ± 2.2 77.1 ± 33.1 24.9 ± 13.8
Heptadecanoic 14.8 ± 2.3 2.4 ± 2.1 27.2 ± 15.1 15.6 ± 12.1 3.7 ± 3.1 32.5 ± 11.5 20.0 ± 10.3
Stearic 242.7 ± 29.8 2.6 ± 1.4 346.9 ± 121.7 103.8 ± 80.7 2.8 ± 1.9 330.6 ± 117.7 90.5 ± 61.8
Oleic 800.1 ± 104.7 3.0 ± 1.8 1203 ± 609 434.2 ± 353.6 3.1 ± 2.0 1141 ± 431 353.3 ± 207.5
Cis-Vaccenic 64.7 ± 8.4 3.0 ± 1.6 83.6 ± 39.5 23.9 ± 18.6 3.5 ± 2.1 89.5 ± 35.7 26.5 ± 16.3
Linoleic 947.4 ± 114.7 3.0 ± 1.8 1152 ± 284 240.1 ±143.4 3.7 ± 2.3 1130 ± 221 177.1 ± 60.8
γ-Linolenic 15.3 ± 1.8 4.0 ± 3.3 20.6 ± 16.9 3.9 ± 2.4 3.4 ± 1.8 15.3 ± 6.1 2.6 ±0.8
α-Linolenic 33.7 ± 4.5 3.3 ± 2.0 78.1 ± 36.5 47.4 ± 23.8 2.9 ± 1.7 77.8 ± 47.4 43.6 ± 27.2
Arachidic 6.1 ± 0.8 3.1 ± 1.9 9.2 ± 4.9 3.4 ± 2.1 3.6 ± 1.8 10.9 ± 3.9 5.0 ±2.4
Dihomo-γ-linolenic 49.7 ± 6.2 5.7 ± 3.8 56.8 ± 13.2 8.9 ± 4.3 6.2 ± 3.3 55.2 ± 12.9 6.4 ± 3.4
Arachidonic 226.7 ± 28.5 6.1 ± 3.8 254.5 ± 56.4 38.1 ± 14.8 6.5 ± 3.7 245.6 ± 67.1 29.2 ± 14.4
EPA 25.6 ± 3.6 6.9 ± 2.2 75.9 ± 24.8 50.1 ± 24.2 7.5 ± 2.0 50.4 ± 14.3* 24.9 ± 6.9**
DPA 19.5 ± 2.6 6.7 ± 3.2 26.1 ± 7.0 7.8 ± 3.8 5.6 ± 2.8 25.0 ± 6.8 5.1 ± 2.4
DHA 55.8 ± 7.1 6.7 ± 2.7 66.7 ± 18.9 13.3 ± 7.9 7.4 ± 2.5 70.1 ± 22.5 14.4 ± 5.5
Data are mean ± SD from 10 participants. * indicates P = 0.010 vs algal oil; ** indicates P = 0.006 vs algal oil.
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time point (Table 4).
MANOVA revealed significant oil x time interactions
for EPA (P = 0.001), DPA (P = 0.032) and DHA (P = 0.049).
There were time-dependent increases in the concentration
of EPA when the participants consumed either algal oil
or krill oil with the test meal (P < 0.001 for both) (Figure 2).
There was also an increase in the concentration of DPA
with algal oil (P < 0.001) and a trend to an increase in DPA
with krill oil (P = 0.083). There were time-dependent
increases in the concentration of DHA when the partici-
pants consumed either algal oil or krill oil with the test
meal (P = 0.027 and P < 0.001, respectively). With both
algal and krill oils EPA concentration was higher than
at time zero at all time points from 2 hours on. With
algal oil DPA concentration was higher than at time
zero at all time points from 3 hours on, while with krill
oil DPA concentration was higher than at time zero at
5 and 10 hours. With algal oil DHA concentration was
not significantly higher than at time zero at any individual
time point, while with krill oil DHA concentration was
higher than at time zero at all time points from 3 hours on.
EPA concentration was significantly higher with algal
oil than with krill oil at 5, 6, 8 and 10 hours (P < 0.05)
and tended to be higher at 4 hours (P = 0.094). DPA,
DHA and arachidonic acid concentrations did not differ
between oils at any time point, although there was a
trend for DHA concentration to be higher with krill oil
at 5 hours (P = 0.083).The time at which each fatty acid reached its peak
concentration (Tmax) is shown in Table 4. Fatty acids
of chain length 18 carbons or less reached their peak
concentration about 3 hours after consuming the test
meal, while PUFAs of 20 carbons or more reached their
peak concentration 6 to 8 hours after consuming the
meal. There were no significant differences in Tmax
between oils for any fatty acid (Table 4).
Table 4 also shows the maximum concentration (Cmax)
for each individual fatty acid. Cmax of EPA was signifi-
cantly higher with algal oil than with krill oil (P = 0.010).
The maximum change in concentration of EPA from its
fasting concentration (MaxΔC) was also significantly
higher with algal oil than with krill oil (P = 0.006).
There were no significant differences in Cmax or MaxΔC
between oils for any fatty acid other than EPA (Table 4).
The area under the concentration curve (AUC) and
the incremental AUC (IAUC) for each fatty acid are
shown in Table 5. The AUC and IAUC for EPA were
greater with algal oil compared with krill oil (P = 0.020
and P = 0.006, respectively), but there was no difference
for the AUC or IAUC for any other fatty acid including
DPA or DHA (Table 5).
Figure 3 shows the change in the concentration of EPA
plus DHA in plasma. Cmax of EPA plus DHA tended to
be higher with algal oil (P = 0.098) and MaxΔC was signifi-
cantly higher with algal oil (P = 0.035). IAUC for EPA plus
DHA also tended to be higher with algal oil (P = 0.076).





























































Figure 1 Changes in the concentrations of 14 to 18 carbon chain length fatty acids when participants consumed a test meal plus
a) algal oil or b) krill oil. Data are mean values from 10 participants. Error bars are omitted for clarity. There were no significant differences
between algal oil and krill oil for any fatty acid at any time point.
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Here we report the changes in fatty acid concentrations in
plasma over 10 hours following consumption of a high fat
breakfast plus supplements providing LC n-3 PUFAs.
Some fatty acids in plasma are in the “free” (i.e. non-
esterified) form but the bulk are esterified to produce
more complex lipids mainly TAGs, PhLs, and cholesteryl
esters. In turn, the complex lipids are components of
lipoproteins whose role is to transport lipids, especially
the fatty acid constituents, between tissues. In lipopro-
teins, the non-polar lipids (TAGs, cholesteryl esters)
form a core which is surrounded by a PhL monolayer.
The TAGs, cholesteryl esters and PhLs have characteristic
fatty acid compositions but both the complex lipid content
and the fatty acid composition of lipoproteins changes
as they are metabolised. After eating, the bulk of fatty
acids derived from the meal appear in the circulation as
components of TAGs within chylomicrons. In the current
study fatty acids of 14 to 18 carbons derived from the meal
appeared quickly in plasma and reached their maximal
concentration around 3 hours after consuming thebreakfast. This is entirely consistent with the time course
of the change in concentration of total TAGs [35-37]
and of chylomicrons [35,37]. The changes in the concen-
trations of 14 to 18 carbon fatty acids in plasma are in
accordance with the relative amounts of those fatty acids
in the breakfast. This agrees with the data presented by
Burdge et al. [36] and fits with current concepts on the
handling of dietary fat [38]. Most of these fatty acids
had returned to their starting concentrations by 8 hours
following the breakfast.
In contrast to 14 to 18 carbon fatty acids, 20 and 22
carbon PUFAs demonstrated a slower rise in concentra-
tion in plasma and reached their maximum concentra-
tions 6 to 8 hours after consuming the breakfast. Again
this pattern of appearance is in agreement with the litera-
ture. Burdge et al. [39] reported appearance of EPA and
DHA in plasma TAGs after subjects consumed a high fat
breakfast containing EPA and DHA and saw that the max-
imum concentrations were not reached until 4 hours after
completing the meal and then were sustained for a further
two hours. They did not make measurements beyond that
Figure 2 Changes in the concentrations of 20 and 22 carbon chain length polyunsaturated fatty acids when participants consumed a
test meal plus algal oil (closed squares) or krill oil (closed diamonds). Data are mean values and their standard deviation from 10 participants.
Significant differences are as follows: EPA: For both oils 2, 2.5, 3, 4, 5, 6, 8 and 10 hours are significantly different from time zero. Algal oil is significantly
greater than krill oil at 5, 6, 8 and 10 hours. DPA: For algal oil 3, 4, 5, 6, 8 and 10 hours are significantly different from time zero. For krill oil 5 and10
hours are significantly different from time zero. DHA: For krill oil 3, 4, 5, 6, 8 and 10 hours are significantly different from time zero.
Table 5 Area under the concentration-time curve (AUC) and incremental AUC for each fatty acid following
consumption of the test meal with algal oil or krill oil
Algal oil Krill oil
Fatty acid AUC ((μg/ml)/hr) IAUC ((μg/ml)/hr) AUC ((μg/ml)/hr) IAUC ((μg/ml)/hr)
Myristic 611 ± 400 250 ± 166 580 ± 250 268 ± 169
Palmitic 8670 ± 3161 1398 ± 931 8394 ± 2432 1170 ± 526
Palmitoleic 753 ± 596 128 ± 93 697 ± 257 105 ± 51
Heptadecanoic 144 ± 62 74 ± 88 165 ± 47 62 ± 30
Stearic 2727 ± 697 419 ± 299 2684 ± 758 365 ± 200
Oleic 8580 ± 3739 1851 ± 1289 8502 ± 2711 1614 ± 968
Cis-Vaccenic 648 ± 251 107 ± 69 689 ± 233 107 ± 62
Linoleic 10025 ± 2027 1102 ± 737 10074 ± 1997 800 ± 337
γ-Linolenic 180 ± 153 22 ± 17 136 ± 59 11 ± 4
α-Linolenic 473 ± 218 198 ± 120 469 ± 216 191 ± 126
Arachidic 69 ± 41 16 ± 13 75 ± 28 17 ± 10
Dihomo-γ-linolenic 518 ± 137 44 ± 31 513 ± 122 31 ± 15
Arachidonic 2342 ± 550 214 ± 107 2290 ± 646 134 ± 81
EPA 533 ± 157 277 ± 135 391 ± 120* 137 ± 39**
DPA 220 ± 58 39 ± 26 214 ± 58 25 ± 12
DHA 582 ± 164 65 ± 45 621 ± 205 70 ± 39
Data are mean ± SD from 10 participants. * indicates P = 0.020 vs algal oil; ** indicates P = 0.006 vs algal oil.
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Figure 3 Changes in the concentrations of EPA+DHA when
participants consumed a test meal plus algal oil (closed
squares) or krill oil (closed diamonds). Data are mean values and
their standard deviation from 10 participants. Significant differences
are as follows: For algal oil 2.5, 3, 4, 5, 6, 8 and 10 hours are
significantly different from time zero. For krill oil 2, 2.5, 3, 4, 5, 6, 8
and 10 hours are significantly different from time zero. There are no
differences between oils at any time point.
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http://www.lipidworld.com/content/12/1/102time point. In the current study EPA and DHA concentra-
tions were maintained at their maximum until 10 hours
after the meal was consumed. Heath et al. [35] reported
EPA and DHA in chylomicron-like particles, chylomicron
remnants, very low density lipoproteins (VLDLs) and
non-esterified fatty acids (NEFAs) over 6 hours following
their consumption. The appearance of EPA and DHA in
chylomicron-like particles was maximal at 3 and 4 hours.
They then tracked into chylomicron remnants peaking
in concentration at 4.5 hours. Finally, they appeared in
VLDLs peaking in concentration at 5-6 hours. EPA con-
centration was greater than DHA in the chylomicron-like
particles and the chylomicron remnants, reflecting the
higher content of EPA than DHA in the test meal [35].
However, DHA concentration was greater than that of
EPA in VLDLs [35], indicating different pathways of me-
tabolism and handling of EPA and DHA over the 6 hours
following their consumption in a meal. Heath et al. [35]
also reported appearance of EPA and DHA, with the
concentration of DHA being greater, in NEFAs in the late
phase of their study. The sequential movement of EPA
and DHA through the various lipoproteins and the relative
enrichment of VLDLs in DHA were confirmed in a
second study by Heath et al. [37]. The later appearance of
EPA and DHA in plasma compared with shorter chain
fatty acids observed in the current study is consistent with
the findings of Burdge et al. and Heath et al. in relation to
the late appearance of EPA and DHA in plasma TAGs and
TAG-rich lipoproteins. It seems likely that in the current
study the EPA and DHA appearing in the plasma over the
first hours is within chylomicrons, as seen by Heath et al.
[35], but that later on these fatty acids are within remnant
particles, VLDLs and NEFAs.
Plasma EPA concentration increased with both algal
and krill oils, but was higher with algal oil reflecting its
higher EPA content. The mean increase in plasma EPAwith algal oil was 100% higher than with krill oil. Partici-
pants consumed 1.5 g EPA from algal oil and 1 g EPA
from krill oil. This suggests that on a gram-per-gram
basis algal oil may be a more effective source of EPA
than krill oil. It is possible that the presence of DHA in
krill oil limits the incorporation of EPA into plasma
lipids. Another possibility is that n-3 PUFAs within
glycolipids, as found in algal oil but not krill oil, are an
effective system for delivering EPA to humans. The
apparently higher incorporation of EPA with algal com-
pared with krill oil is particularly interesting because a
recent study reported better incorporation of EPA into
plasma over 72 hours if participants consumed krill oil
compared with if they consumed TAGs, both providing
the same amounts of EPA and DHA [27]. Taking this
finding together with that of the current study suggests
that an EPA-rich algal oil may be a very effective way of
enhancing EPA status in humans. This will need to be
studied in longer term intervention studies that assess
other functional pools such as leukocytes and red cells
[34] and link the fatty acid changes observed to physio-
logical effects of relevance to human health [1].
Plasma DHA concentration clearly increased with krill
oil as shown by the significant relationship between time
and DHA concentration and by the significant differences
in DHA concentration between time zero and all time
points from 3 hours on when the participants consumed
krill oil. Nevertheless, plasma DHA concentration did
not differ between algal and krill oils at any time point,
even though krill oil contains DHA and the algal oil
does not. This is because there was a small increase in
concentration of DHA with algal oil seen as a significant
relationship between time and DHA concentration. It is
not clear why this might be, although the effect is
sufficiently small that there was no difference in DHA
concentration between time zero and any subsequent time
point when participants consumed algal oil. It is generally
considered that there is poor conversion of EPA to
DPA and especially to DHA [2,40]. It is possible that
enterocytes may be able to carry out this metabolic
transformation, but the rather late appearance of DPA
and DHA with algal oil suggests that enterocyte biosyn-
thesis of these two fatty acids is not likely to be involved.
There is more likely to be a metabolic explanation for
these observations. It is possible that DHA, and perhaps
also DPA, become preferentially concentrated in VLDLs
late in the post-prandial period, as suggested by the
observations of Heath et al. [35]. Thus, the appearance
of increasing concentrations of DHA in plasma beyond
5 to 6 hours with algal oil may reflect continued accu-
mulation of DHA in lipoproteins synthesised in the
liver (VLDLs) using DHA from remnant lipoproteins
and NEFAs while at the same time limiting, or perhaps
preventing, DHA oxidation.
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Consuming a polar-lipid rich oil from the microalgae
Nannochloropsis oculata or krill oil results in significant
appearance of EPA in human plasma. There is also
appearance of DPA and DHA. Algal oil results in a greater
concentration of EPA in plasma than krill oil, even taking
into account the different EPA contents of the two oils.
This difference may relate to the different chemical con-
stituents of the two oils namely the presence of glycolipids.
This study demonstrates that polar-lipid rich oil from
Nannochloropsis oculata is an effective source of EPA in
humans.
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